Dr. Miksad's research goal is to improve treatments and outcomes for patients with Hepatobiliary and Pancreatic Cancer. She is engaged in translational clinical trial and health services/outcomes research as an Attending Physician in medical oncology at Beth Israel Deaconess Medical Center and as Senior Scientist at the Institute for Technology Assessment at Massachusetts General Hospital. Dr. Miksad's research is currently supported by a K23 from the National Cancer Institute.
Dr. Miksad's past research support includes the Young InvestigatorAward from the American Society of Clinical Oncology, the DF/HCC Program in Cancer Outcomes Research (PCORT) fellowship, the Young Investigator’s Award from the American Society of Clinical Oncology, the Timely Special Opportunity Award from the Dana-Farber Cancer Institute, the NIH Loan Repayment Program and the Clinical Research Feasibility Fund Award from BIDMC. Recent awards include the Lee Lusted Prize for outstanding research from the Society for Medical Decision Making and the Clinical Research Award from the Eastern Cooperative Oncology Group.
Dr. Miksad received a B.A in economics from Harvard, an MD with honors in research from Cornell University, and an MPH from Harvard. She completed her internal medicine residency at New York-Presbyterian Hospital and her Hematology/Oncology fellowship at BIDMC. She completed the NCI-funded post-doctoral fellowship in the Dana-Farber/Harvard Cancer Center Program in Cancer Outcomes Research Training (PCORT). Rebecca’s research goals are to improve oncology treatment decision making through better characterization of cancer patient outcomes, improved accuracy of clinical endpoints, assessment of the economic implications of cancer therapy and application of decision analysis tools. Dr. Miksad current and recent research projects include:
1) Efficacy neoadjuvant sorafenib for radiofrequency ablation of localized hepatocellular carcinoma (HCC)
2) Hepatobiliary cancer clinical trials and liver cancer outcomes
3) Surrogate endpoint evaluation and validation in cancer trials
4) Bayesian analysis / novel oncology clinical trial evaluation
5) Decision analysis and cancer modeling
6) Quality of life of cancer patients